Pharnext rare dis­ease drug scores in late-stage study, tee­ing up ap­pli­ca­tions at the FDA and EMA

French drug de­vel­op­er Pharnext SAS says their cru­cial late-stage study has come through with sig­nif­i­cant re­sults for a new drug to ad­dress a rare neu­ro­log­i­cal dis­ease that has so far elud­ed treat­ment. The com­pa­ny’s stock (EPA: $AL­PHA) soared 25% Tues­day morn­ing af­ter it an­nounced that the ex­per­i­men­tal treat­ment for Char­cot-Marie-Tooth (CMT) dis­ease was com­pelling enough to ap­ply for FDA and EMA ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER